Journal article
Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals
LM Van Der Kall, T Truong, SC Burnham, V Doré, RS Mulligan, S Bozinovski, F Lamb, P Bourgeat, J Fripp, S Schultz, YY Lim, SM Laws, D Ames, C Fowler, SR Rainey-Smith, RN Martins, O Salvado, J Robertson, P Maruff, CL Masters Show all
Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021
Abstract
ObjectiveTo determine the effect of β-amyloid (Aβ) level on progression risk to mild cognitive impairment (MCI) or dementia and longitudinal cognitive change in cognitively normal (CN) older individuals.MethodsAll CN from the Australian Imaging Biomarkers and Lifestyle study with Aβ PET and ≥3 years follow-up were included (n = 534; age 72 ± 6 years; 27% Aβ positive; follow-up 5.3 ± 1.7 years). Aβ level was divided using the standardized 0-100 Centiloid scale: 100 CL very high, noting >25 CL approximates a positive scan. Cox proportional hazards analysis and linear mixed effect models were used to assess risk of progression and cognitive decline.ResultsAβ levels in 63% were negative, 10% unc..
View full abstractRelated Projects (2)
Grants
Awarded by Science and Industry Endowment Fund
Funding Acknowledgements
Core funding for the study was provided by the CSIRO Flagship Collaboration Fund and the Science and Industry Endowment Fund in partnership with Austin Health, University of Melbourne, Edith Cowan University, Florey Institute of Neuroscience and Mental Health, Alzheimer's Australia, and the National Ageing Research Institute. The study also received funding from the National Health and Medical Research Council, the Dementia Collaborative Research Centres program, the McCusker Alzheimer's Research Foundation, and Operational Infrastructure Support from the Government of Victoria.